Zoledronic Acid increased hip BMD in acute Charcot neuroarthropathy .
Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: A prospective randomized trial
Foot Ankle Surg. 2013 Jun;19(2):121-4. doi: 10.1016/j.fas.2012.12.007. Epub 2013 Feb 2035 patients, suffering from acute midfoot Charcot neuropathy (CNA), were randomized to study the effects of zoledronic acid and immobilization on Bone Mineral Density (BMD) changes in lumbar spine and both hips. Patients were assigned to either receive zoledronic acid or a placebo treatment. 6 month results demonstrated a rise in hip BMD in zoledronic acid-treated group, and a fall in affected and non-affected CNA hip BMD in the placebo group. Immobilization and off-loading did not show signs of disuse osteoporosis.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
